Cargando…

The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER)

SIMPLE SUMMARY: Controlled clinical trials are one of the most important sources of medical knowledge, but their results are not always identical to those observed later in normal day-to-day practice. Therefore, real-world studies are needed to investigate those differences. The targeted agents cetu...

Descripción completa

Detalles Bibliográficos
Autores principales: Potocki, Paweł Michał, Wiśniowski, Rafał, Haus, Dominik, Chowaniec, Zbyszko, Kozaczka, Maciej, Kustra, Magdalena, Samborska-Plewicka, Marzenna, Szweda, Marcin, Starzyczny-Słota, Danuta, Michalik, Magdalena, Słomian, Grzegorz, Lebiedzińska, Aneta, Jonak-Olczyk, Natalia, Łaszewska-Kraińska, Natalia, Adamowicz, Krzysztof, Kolenda, Piotr, Drosik-Kwaśniewska, Anna, Szwiec, Marek, Dziura, Robert, Czech, Justyna, Dąbrowska, Maria, Nowakowska-Zajdel, Ewa, Klank-Sokołowska, Ewa, Konopka, Kamil, Kwinta, Łukasz, Dobrzańska, Jolanta, Wysocki, Piotr J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487009/
https://www.ncbi.nlm.nih.gov/pubmed/37686636
http://dx.doi.org/10.3390/cancers15174361
_version_ 1785103133162078208
author Potocki, Paweł Michał
Wiśniowski, Rafał
Haus, Dominik
Chowaniec, Zbyszko
Kozaczka, Maciej
Kustra, Magdalena
Samborska-Plewicka, Marzenna
Szweda, Marcin
Starzyczny-Słota, Danuta
Michalik, Magdalena
Słomian, Grzegorz
Lebiedzińska, Aneta
Jonak-Olczyk, Natalia
Łaszewska-Kraińska, Natalia
Adamowicz, Krzysztof
Kolenda, Piotr
Drosik-Kwaśniewska, Anna
Szwiec, Marek
Dziura, Robert
Czech, Justyna
Dąbrowska, Maria
Nowakowska-Zajdel, Ewa
Klank-Sokołowska, Ewa
Konopka, Kamil
Kwinta, Łukasz
Dobrzańska, Jolanta
Wysocki, Piotr J.
author_facet Potocki, Paweł Michał
Wiśniowski, Rafał
Haus, Dominik
Chowaniec, Zbyszko
Kozaczka, Maciej
Kustra, Magdalena
Samborska-Plewicka, Marzenna
Szweda, Marcin
Starzyczny-Słota, Danuta
Michalik, Magdalena
Słomian, Grzegorz
Lebiedzińska, Aneta
Jonak-Olczyk, Natalia
Łaszewska-Kraińska, Natalia
Adamowicz, Krzysztof
Kolenda, Piotr
Drosik-Kwaśniewska, Anna
Szwiec, Marek
Dziura, Robert
Czech, Justyna
Dąbrowska, Maria
Nowakowska-Zajdel, Ewa
Klank-Sokołowska, Ewa
Konopka, Kamil
Kwinta, Łukasz
Dobrzańska, Jolanta
Wysocki, Piotr J.
author_sort Potocki, Paweł Michał
collection PubMed
description SIMPLE SUMMARY: Controlled clinical trials are one of the most important sources of medical knowledge, but their results are not always identical to those observed later in normal day-to-day practice. Therefore, real-world studies are needed to investigate those differences. The targeted agents cetuximab and panitumumab, combined with chemotherapy, are an effective treatment for metastatic colon cancer, provided that certain mutations have not occurred in cancer cells (namely activating mutations in KRAS, NRAS or BRAF genes). Recently, it was found that the outcomes of the aforementioned therapy differ depending on which part of the colon the tumour originates from. We conducted a real-world study on 842 patients treated at 16 cancer centres. The study confirmed that metastatic cancer that originated in the right part of the colon has a lower response to cetuximab or panitumumab-based treatment. ABSTRACT: Anti-EGFR antibodies combined with chemotherapy doublets are a cornerstone of the upfront treatment of colorectal cancer. RAS and BRAF mutations are established negative predictive factors for such therapy. The primary tumour located in the proximal colon has recently emerged as another negative predictive factor. We have conducted a retrospective multicentre study to collect data on real-world population characteristics, practice patterns, and outcomes in patients with metastatic colorectal cancer treated in a first-line setting with either cetuximab or panitumumab in combination with either FOLFOX or FOLFIRI chemotherapy. The presented analysis focuses on the impact of the primary tumour location. 126 of 842 patients analysed (15.0%) had proximal primary. It was associated with a lower BMI at diagnosis, mucinous histology, and peritoneal metastases. It was also associated with inferior treatment outcomes in terms of response ratio: 59.4% vs. 74.22% (odds ratio [OR] 0.51, 95% CI 0.33–0.78, p = 0.010), and median depth of response: −36.7% vs. −50.0% (p = 0.038). There was only a borderline non-significant trend for inferior PFS in patients with proximal tumours. OS data was incomplete. The presented analysis confirms the negative impact of tumour sidedness on the efficacy of an upfront anti-EGFR-chemotherapy combination and provides valuable data on real-world population characteristics.
format Online
Article
Text
id pubmed-10487009
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104870092023-09-09 The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER) Potocki, Paweł Michał Wiśniowski, Rafał Haus, Dominik Chowaniec, Zbyszko Kozaczka, Maciej Kustra, Magdalena Samborska-Plewicka, Marzenna Szweda, Marcin Starzyczny-Słota, Danuta Michalik, Magdalena Słomian, Grzegorz Lebiedzińska, Aneta Jonak-Olczyk, Natalia Łaszewska-Kraińska, Natalia Adamowicz, Krzysztof Kolenda, Piotr Drosik-Kwaśniewska, Anna Szwiec, Marek Dziura, Robert Czech, Justyna Dąbrowska, Maria Nowakowska-Zajdel, Ewa Klank-Sokołowska, Ewa Konopka, Kamil Kwinta, Łukasz Dobrzańska, Jolanta Wysocki, Piotr J. Cancers (Basel) Article SIMPLE SUMMARY: Controlled clinical trials are one of the most important sources of medical knowledge, but their results are not always identical to those observed later in normal day-to-day practice. Therefore, real-world studies are needed to investigate those differences. The targeted agents cetuximab and panitumumab, combined with chemotherapy, are an effective treatment for metastatic colon cancer, provided that certain mutations have not occurred in cancer cells (namely activating mutations in KRAS, NRAS or BRAF genes). Recently, it was found that the outcomes of the aforementioned therapy differ depending on which part of the colon the tumour originates from. We conducted a real-world study on 842 patients treated at 16 cancer centres. The study confirmed that metastatic cancer that originated in the right part of the colon has a lower response to cetuximab or panitumumab-based treatment. ABSTRACT: Anti-EGFR antibodies combined with chemotherapy doublets are a cornerstone of the upfront treatment of colorectal cancer. RAS and BRAF mutations are established negative predictive factors for such therapy. The primary tumour located in the proximal colon has recently emerged as another negative predictive factor. We have conducted a retrospective multicentre study to collect data on real-world population characteristics, practice patterns, and outcomes in patients with metastatic colorectal cancer treated in a first-line setting with either cetuximab or panitumumab in combination with either FOLFOX or FOLFIRI chemotherapy. The presented analysis focuses on the impact of the primary tumour location. 126 of 842 patients analysed (15.0%) had proximal primary. It was associated with a lower BMI at diagnosis, mucinous histology, and peritoneal metastases. It was also associated with inferior treatment outcomes in terms of response ratio: 59.4% vs. 74.22% (odds ratio [OR] 0.51, 95% CI 0.33–0.78, p = 0.010), and median depth of response: −36.7% vs. −50.0% (p = 0.038). There was only a borderline non-significant trend for inferior PFS in patients with proximal tumours. OS data was incomplete. The presented analysis confirms the negative impact of tumour sidedness on the efficacy of an upfront anti-EGFR-chemotherapy combination and provides valuable data on real-world population characteristics. MDPI 2023-09-01 /pmc/articles/PMC10487009/ /pubmed/37686636 http://dx.doi.org/10.3390/cancers15174361 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Potocki, Paweł Michał
Wiśniowski, Rafał
Haus, Dominik
Chowaniec, Zbyszko
Kozaczka, Maciej
Kustra, Magdalena
Samborska-Plewicka, Marzenna
Szweda, Marcin
Starzyczny-Słota, Danuta
Michalik, Magdalena
Słomian, Grzegorz
Lebiedzińska, Aneta
Jonak-Olczyk, Natalia
Łaszewska-Kraińska, Natalia
Adamowicz, Krzysztof
Kolenda, Piotr
Drosik-Kwaśniewska, Anna
Szwiec, Marek
Dziura, Robert
Czech, Justyna
Dąbrowska, Maria
Nowakowska-Zajdel, Ewa
Klank-Sokołowska, Ewa
Konopka, Kamil
Kwinta, Łukasz
Dobrzańska, Jolanta
Wysocki, Piotr J.
The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER)
title The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER)
title_full The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER)
title_fullStr The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER)
title_full_unstemmed The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER)
title_short The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER)
title_sort impact of sidedness on the efficacy of anti-egfr-based first-line chemotherapy in advanced colorectal cancer patients in real-life setting—a nation-wide retrospective analysis (racer)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487009/
https://www.ncbi.nlm.nih.gov/pubmed/37686636
http://dx.doi.org/10.3390/cancers15174361
work_keys_str_mv AT potockipawełmichał theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT wisniowskirafał theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT hausdominik theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT chowanieczbyszko theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT kozaczkamaciej theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT kustramagdalena theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT samborskaplewickamarzenna theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT szwedamarcin theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT starzycznysłotadanuta theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT michalikmagdalena theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT słomiangrzegorz theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT lebiedzinskaaneta theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT jonakolczyknatalia theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT łaszewskakrainskanatalia theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT adamowiczkrzysztof theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT kolendapiotr theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT drosikkwasniewskaanna theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT szwiecmarek theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT dziurarobert theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT czechjustyna theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT dabrowskamaria theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT nowakowskazajdelewa theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT klanksokołowskaewa theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT konopkakamil theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT kwintałukasz theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT dobrzanskajolanta theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT wysockipiotrj theimpactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT potockipawełmichał impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT wisniowskirafał impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT hausdominik impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT chowanieczbyszko impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT kozaczkamaciej impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT kustramagdalena impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT samborskaplewickamarzenna impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT szwedamarcin impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT starzycznysłotadanuta impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT michalikmagdalena impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT słomiangrzegorz impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT lebiedzinskaaneta impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT jonakolczyknatalia impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT łaszewskakrainskanatalia impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT adamowiczkrzysztof impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT kolendapiotr impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT drosikkwasniewskaanna impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT szwiecmarek impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT dziurarobert impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT czechjustyna impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT dabrowskamaria impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT nowakowskazajdelewa impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT klanksokołowskaewa impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT konopkakamil impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT kwintałukasz impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT dobrzanskajolanta impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer
AT wysockipiotrj impactofsidednessontheefficacyofantiegfrbasedfirstlinechemotherapyinadvancedcolorectalcancerpatientsinreallifesettinganationwideretrospectiveanalysisracer